1:21 PM
 | 
Nov 16, 2017
 |  BC Extra  |  Company News

FDA approves Genentech's Hemlibra for hemophilia A

Editor's Note: This article was updated on Nov 16, 2017 at 3:35 PM PST

FDA approved once-weekly subcutaneous Hemlibra emicizumab-kxwh from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >